Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caimiao Wei

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Annals of Surgery|September 26, 2007
Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomasPeter W T Pisters, Raphael E Pollock, Valerae O Lewis, et al.
Journal of Cancer|March 14, 2015
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Caimiao Wei, et al.
Scientific Reports|May 24, 2020
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancerMaria Gagliardi, Mary Kathryn Pitner, Jihyun Park, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeW Fraser Symmans, Caimiao Wei, Rebekah Gould, et al.
Nature Medicine|May 31, 2025
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Future Oncology (London, England)|May 24, 2026
Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summaryNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Urology|February 4, 2014
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysisJamie C Messer, Shahrokh F Shariat, Colin P Dinney, et al.
Nature Medicine|July 21, 2025
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Oncotarget|November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patientsReva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Annals of Surgery|September 26, 2007
Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomasPeter W T Pisters, Raphael E Pollock, Valerae O Lewis, et al.
Journal of Cancer|March 14, 2015
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Caimiao Wei, et al.
Scientific Reports|May 24, 2020
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancerMaria Gagliardi, Mary Kathryn Pitner, Jihyun Park, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeW Fraser Symmans, Caimiao Wei, Rebekah Gould, et al.
Nature Medicine|May 31, 2025
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Future Oncology (London, England)|May 24, 2026
Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summaryNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Urology|February 4, 2014
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysisJamie C Messer, Shahrokh F Shariat, Colin P Dinney, et al.
Nature Medicine|July 21, 2025
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Oncotarget|November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patientsReva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
Pageof 7